{"product_id":"eldn-vrio-analysis","title":"Eledon Pharmaceuticals, Inc. (ELDN): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking sustainable competitive advantage is the ultimate goal, and our deep-dive VRIO analysis of Eledon Pharmaceuticals, Inc. (ELDN) reveals precisely where its core strengths lie - assessing the Value, Rarity, Inimitability, and Organization of its key resources, as summarized by \u0026amp;O4\u0026amp;. Discover the critical factors driving Eledon Pharmaceuticals, Inc. (ELDN)'s market position and what it means for its future success by reading the full breakdown below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEledon Pharmaceuticals, Inc. (ELDN) - VRIO Analysis: Tegoprubart’s Differentiated Safety Profile (Anti-CD40L Antibody)\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at Eledon Pharmaceuticals, Inc. (ELDN) through the lens of Tegoprubart, and the story right now is all about the safety gap it appears to create versus the incumbent, tacrolimus. The key takeaway from the November 2025 data is that this drug offers a potential pathway to maintain efficacy while drastically cutting down on the side effects that plague transplant patients. Honestly, this is what drives the entire investment thesis right now.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: It offers a potential replacement for tacrolimus by maintaining efficacy while substantially reducing common, debilitating toxicities like tremor and new-onset diabetes.\u003c\/strong\u003e The Phase 2 BESTOW trial results, presented in November 2025, clearly quantify this value proposition. While the primary efficacy endpoint wasn't statistically met, the drug demonstrated non-inferiority on the composite endpoint of efficacy failure (death, graft loss, acute rejection) at 22% versus 17% for tacrolimus. More importantly, the safety profile looks significantly better, which is where the real market opportunity lies for a replacement therapy.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the toxicity reduction from the BESTOW trial data:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdverse Event\u003c\/td\u003e\n\u003ctd\u003eTegoprubart (n=51)\u003c\/td\u003e\n\u003ctd\u003eTacrolimus (n=56)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew-Onset Diabetes\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1 in 47\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1 in 6\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTremor\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHypertension\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHeart Failure\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eWhat this estimate hides is the potential for better long-term quality of life, which is hard to price but crucial for physician adoption. Also, note the 12-month estimated glomerular filtration rate (eGFR) was 69 mL\/min\/1.73 m² for Tegoprubart versus 66 mL\/min\/1.73 m² for tacrolimus.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: The specific, favorable toxicity profile compared to current standard-of-care immunosuppressants is rare in late-stage transplant candidates.\u003c\/strong\u003e Finding a drug that matches the efficacy of a decades-old standard like tacrolimus while avoiding its known, debilitating side effects is exceptionally rare in late-stage development. This differentiated safety profile is what makes Tegoprubart stand out from other candidates in the pipeline, especially given the historical context where improving safety often meant sacrificing efficacy.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: High, as replicating the specific clinical safety data and the drug's unique binding characteristics would require years of R\u0026amp;D.\u003c\/strong\u003e The barrier to entry here isn't just the molecule; it's the clinical evidence base Eledon has built. You can’t just copy the drug; you have to replicate the years of patient data showing these specific, favorable outcomes. This is a significant moat, defintely.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Strong, evidenced by the CEO highlighting this safety profile immediately following the November 2025 data presentation.\u003c\/strong\u003e Management is clearly aligned on the narrative. Following the November 6 presentation, CEO David-Alexandre C. Gros, M.D., immediately framed the drug as a next-generation option based on this safety profile. Furthermore, the organization has acted on its conviction by completing an underwritten public offering in November 2025, raising gross proceeds of $57.5 million to fund the path forward, even as their cash position stood at $93.4 million as of September 30, 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained, provided Phase 3 confirms these safety and efficacy signals.\u003c\/strong\u003e The current advantage is \u003cem\u003epotential\u003c\/em\u003e and \u003cem\u003etemporary\u003c\/em\u003e until the Phase 3 trial design is agreed upon with regulators and that study is completed. If Phase 3 replicates the BESTOW findings, the advantage becomes sustained because the drug will be positioned as the superior, safer standard of care, which is a powerful position in transplant medicine. The plan is to initiate that Phase 3 trial in 2026.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEledon Pharmaceuticals, Inc. (ELDN) - VRIO Analysis: Broad Multi-Organ Transplant Platform\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows for multiple shots on goal across kidney, islet cell (T1D), liver, and xenotransplantation, diversifying risk.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eKidney Transplant Phase 2 BESTOW trial 12-month eGFR was approximately \u003cstrong\u003e69 mL\/min\/1.73\u003csup\u003e2\u003c\/sup\u003e\u003c\/strong\u003e for participants in the tegoprubart treatment arm (n=51).\u003c\/li\u003e\n\u003cli\u003eIslet Cell Transplant (T1D) preliminary data showed the first \u003cstrong\u003esix\u003c\/strong\u003e subjects achieved sustained insulin independence.\u003c\/li\u003e\n\u003cli\u003eXenotransplantation utilized tegoprubart in the second genetically modified pig kidney transplant in a human in \u003cstrong\u003eJanuary 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; while many firms target transplantation, few have active clinical programs across this many distinct solid organ and islet indications.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; the underlying CD40L biology is known, but the specific application across all these areas is proprietary.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Effective, as the company is actively advancing programs in all four areas as of late 2025.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company completed an underwritten public offering resulting in gross proceeds of \u003cstrong\u003e$57.5 million\u003c\/strong\u003e to advance transplantation programs.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 net loss was \u003cstrong\u003e$17.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents, and short-term investments totaled \u003cstrong\u003e$93.4 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as competitors could focus on one or two of these areas, but Eledon has first-mover advantage in several.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIndication Area\u003c\/th\u003e\n\u003cth\u003eClinical Status\/Key Data Point\u003c\/th\u003e\n\u003cth\u003ePatient\/Subject Count\u003c\/th\u003e\n\u003cth\u003eRelevant Financial Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKidney Allograft\u003c\/td\u003e\n\u003ctd\u003ePhase 2 BESTOW 12-month eGFR: \u003cstrong\u003e69 mL\/min\/1.73\u003csup\u003e2\u003c\/sup\u003e\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003en=\u003cstrong\u003e51\u003c\/strong\u003e (Phase 2 arm)\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 R\u0026amp;D Expenses: \u003cstrong\u003e$15.0 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIslet Cell (T1D)\u003c\/td\u003e\n\u003ctd\u003eAchieved sustained insulin independence without calcineurin inhibition\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eSix\u003c\/strong\u003e subjects reported; trial extended to \u003cstrong\u003e12\u003c\/strong\u003e subjects\u003c\/td\u003e\n\u003ctd\u003eTrailing EPS: \u003cstrong\u003e-$1.06\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXenotransplantation\u003c\/td\u003e\n\u003ctd\u003eThird patient treated with tegoprubart following pig kidney transplant in \u003cstrong\u003eJune 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eThree\u003c\/strong\u003e patients treated as of August 2025\u003c\/td\u003e\n\u003ctd\u003eGross Proceeds from recent financing: \u003cstrong\u003e$57.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiver Allograft\u003c\/td\u003e\n\u003ctd\u003ePreclinical data showed markedly prolonged graft survival in NHPs\u003c\/td\u003e\n\u003ctd\u003ePreclinical (NHPs)\u003c\/td\u003e\n\u003ctd\u003eCash, cash equivalents, and short-term investments: \u003cstrong\u003e$93.4 million\u003c\/strong\u003e (Sep 30, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eEledon Pharmaceuticals, Inc. (ELDN) - VRIO Analysis: Phase 2 BESTOW Trial Efficacy Data\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nProvides the foundation for Phase 3 planning, showing strong renal function maintenance with a mean 12-month eGFR of approximately \u003cstrong\u003e69 mL\/min\/1.73m2\u003c\/strong\u003e in the treatment arm (n=51). The mean 12-month eGFR for the tacrolimus arm was \u003cstrong\u003e66 mL\/min\/1.73m2\u003c\/strong\u003e (n=56).\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nHigh; this specific eGFR level in a Phase 2 trial for rejection prevention is what the company believes is the \u003cstrong\u003e'highest to be reported to date'\u003c\/strong\u003e in such a trial.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nLow; this specific clinical data set is unique to Eledon Pharmaceuticals.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nExcellent; the data was presented as a late-breaking oral presentation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting on November 6, 2025, and immediately used to drive regulatory discussions for Phase 3. The company expects current cash, cash equivalents and short-term investments to fund operations to \u003cstrong\u003elate 2026\u003c\/strong\u003e. Estimated cash, cash equivalents and short-term investments totaled approximately \u003cstrong\u003e$93.4 million as of September 30, 2025\u003c\/strong\u003e. The company also secured \u003cstrong\u003e$57.5 million in financing\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nSustained, as this data point becomes a benchmark against which future therapies will be measured.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eTegoprubart Arm (n=51)\u003c\/td\u003e\n\u003ctd\u003eTacrolimus Arm (n=56)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMean 12-Month eGFR (mL\/min\/1.73m2)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e69\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e66\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEfficacy Failure Composite Endpoint (%)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e22%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e17%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDonor-Specific Antibodies (DSA) Cases\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew-Onset Diabetes Patients\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1 in 47\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1 in 6\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTransplant-Associated Hypertension (%)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMean Days of Dialysis for DGF\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4.6 days\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6.1 days\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\nThe efficacy failure composite endpoint, comprising death, graft loss, and biopsy-proven acute rejection, was \u003cstrong\u003e22%\u003c\/strong\u003e in the tegoprubart group versus \u003cstrong\u003e17%\u003c\/strong\u003e in the tacrolimus group, which is within the non-inferiority range.\n\u003c\/li\u003e\n\u003cli\u003e\nSubgroup analysis for living-related donor recipients showed a mean eGFR of approximately \u003cstrong\u003e72 mL\/min\/1.73 m2\u003c\/strong\u003e on tegoprubart versus \u003cstrong\u003e62 mL\/min\/1.73 m2\u003c\/strong\u003e on tacrolimus.\n\u003c\/li\u003e\n\u003cli\u003e\nSubgroup analysis for high KDPI (\u0026gt; 35) transplants showed a mean eGFR of approximately \u003cstrong\u003e62 mL\/min\/1.73 m2\u003c\/strong\u003e on tegoprubart versus \u003cstrong\u003e53 mL\/min\/1.73 m2\u003c\/strong\u003e on tacrolimus.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eEledon Pharmaceuticals, Inc. (ELDN) - VRIO Analysis: Deep Anti-CD40 Ligand Biology Expertise\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eDeep Anti-CD40 Ligand Biology Expertise\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric Category\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Efficacy (Phase 2 BESTOW)\u003c\/td\u003e\n\u003ctd\u003eMean 12-Month eGFR (Tegoprubart)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e69 mL\/min\/1.73 m²\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Efficacy (Phase 1b)\u003c\/td\u003e\n\u003ctd\u003eMean 12-Month eGFR (Tegoprubart)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e68 mL\/min\/1.73 m²\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Position (as of September 30, 2025)\u003c\/td\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Position (as of December 31, 2024)\u003c\/td\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Short-Term Investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$140.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Investment (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Trial Comparison (BESTOW)\u003c\/td\u003e\n\u003ctd\u003eEfficacy Failure Composite Endpoint (Tegoprubart Group)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e22%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAssessment of VRIO Attributes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eValue: This historical knowledge drives the development of tegoprubart and positions the company to understand the mechanism of action (MOA) better than newcomers.\u003c\/li\u003e\n\u003cli\u003eRarity: High; deep, focused expertise in a specific, potent pathway like CD40L is rare outside of established large pharma or focused biotechs.\u003c\/li\u003e\n\u003cli\u003eImitability: Low; this is tacit knowledge built over years of research and preclinical\/clinical work.\u003c\/li\u003e\n\u003cli\u003eOrganization: Strong; the company built its entire lead product around this target.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eCompetitive Advantage Assessment:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCompetitive Advantage: Sustained, as this institutional knowledge informs future pipeline decisions and trial design.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEledon Pharmaceuticals, Inc. (ELDN) - VRIO Analysis: Xenotransplantation Program Advancement\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Positions Eledon Pharmaceuticals at the forefront of a potentially massive future market by using tegoprubart in pig-to-human transplants.\u003c\/p\u003e\n\n\u003cp\u003eThe value proposition is underscored by clinical outcomes, such as the patient in the second xenotransplant being discharged from the hospital without the need for continued treatment with dialysis for the first time in more than two years following the procedure on \u003cstrong\u003eJanuary 25, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMilestone Event\u003c\/th\u003e\n\u003cth\u003eDate\u003c\/th\u003e\n\u003cth\u003eLocation\/Partner\u003c\/th\u003e\n\u003cth\u003eTegoprubart Role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSecond Pig-to-Human Kidney Transplant\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJanuary 25, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMassachusetts General Hospital (MGH) \/ eGenesis\u003c\/td\u003e\n\u003ctd\u003eLead component of immunosuppression treatment regimen\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eThird Pig-to-Human Kidney Transplant\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJune 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMassachusetts General Hospital (MGH) \/ eGenesis\u003c\/td\u003e\n\u003ctd\u003eCornerstone component of the immunosuppression treatment regimen\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFirst Islet Cell Transplant Recipients (T1D)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2025 Year-to-Date (as of Aug 2025)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUniversity of Chicago Medicine's Transplant Institute\u003c\/td\u003e\n\u003ctd\u003ePart of immunosuppression regimen, achieved insulin independence in first three recipients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; being involved in the second pig-to-human kidney transplant using their drug in \u003cstrong\u003eJanuary 2025\u003c\/strong\u003e is a unique, high-profile achievement, followed by a \u003cstrong\u003ethird\u003c\/strong\u003e such transplant in \u003cstrong\u003eJune 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; requires specific institutional relationships (like with Massachusetts General Hospital and eGenesis) and successful early-stage application.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good; they have a clear intent to outline an approval plan for this indication, evidenced by the progression of clinical trials and planned data readouts.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eTopline results from the Phase 2 BESTOW trial in kidney transplantation are anticipated in \u003cstrong\u003eNovember 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents and short-term investments totaled \u003cstrong\u003e$107.6 million\u003c\/strong\u003e as of \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e, with expectations to fund operations to the end of \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eUpdated data from the ongoing open-label Phase 1b trial (as of August 2025) included \u003cstrong\u003e32 participants\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe mean 12-month estimated glomerular filtration rate (eGFR) from the Phase 1b trial was approximately \u003cstrong\u003e68 mL\/min\/1.73 m2\u003c\/strong\u003e post-transplant for patients on tegoprubart (Q2 2025 data).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, but significant now, as success in this area could leapfrog competitors in the broader transplant space.\u003c\/p\u003e\n\n\u003cp\u003eThe use of tegoprubart in the second pig-to-human kidney transplant followed \u003cstrong\u003eFDA approval\u003c\/strong\u003e granted to MGH in \u003cstrong\u003eDecember 2024\u003c\/strong\u003e to proceed with the transplant.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEledon Pharmaceuticals, Inc. (ELDN) - VRIO Analysis: Type 1 Diabetes\/Islet Cell Transplant Data\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOpens a massive, high-unmet-need market by potentially offering a tacrolimus-free regimen leading to insulin independence for T1D patients.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh; preliminary data shows sustained insulin independence, with one patient maintaining an HbA1c as low as \u003cstrong\u003e4.7%\u003c\/strong\u003e for over \u003cstrong\u003e15 months\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLow; this specific clinical outcome data is proprietary.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDeveloping; the trial is investigator-led at UChicago Medicine, with the ongoing trial extended to include a total of \u003cstrong\u003e12 subjects\u003c\/strong\u003e. Eledon is planning to transition it to a registrational study.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained, if the UChicago data translates into a registrational trial success, creating a second major franchise.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eClinical Outcome Data Summary (Tegoprubart Regimen)\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003ePatient 1 (42F)\u003c\/td\u003e\n\u003ctd\u003ePatient 2 (30F)\u003c\/td\u003e\n\u003ctd\u003ePatient 3 (37M)\u003c\/td\u003e\n\u003ctd\u003eSubjects 4 \u0026amp; 5\u003c\/td\u003e\n\u003ctd\u003eSubject 6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInsulin Independence\u003c\/td\u003e\n\u003ctd\u003eAchieved post-second transplant\u003c\/td\u003e\n\u003ctd\u003eAchieved at \u003cstrong\u003e4 weeks\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eTrajectory towards independence\u003c\/td\u003e\n\u003ctd\u003eAchieved within approx. \u003cstrong\u003e4 weeks\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eInsulin free post-second infusion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHbA1c (Post-Tx)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5.4%\u003c\/strong\u003e (after 2nd Tx)\u003c\/td\u003e\n\u003ctd\u003e$\\le$ \u003cstrong\u003e5.8%\u003c\/strong\u003e (at \u003cstrong\u003e7 weeks\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eBelow \u003cstrong\u003e6%\u003c\/strong\u003e (for over \u003cstrong\u003e3 months\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBaseline Insulin Use\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e80 units\/day\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e60 units\/day\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e90 units\/day\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInsulin Use Change\u003c\/td\u003e\n\u003ctd\u003eTo \u003cstrong\u003e16 units\/day\u003c\/strong\u003e at \u003cstrong\u003e90 days\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eStopped at \u003cstrong\u003e4 weeks\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eReduced by more than \u003cstrong\u003e60%\u003c\/strong\u003e at \u003cstrong\u003e3 days\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEngraftment vs. Tacrolimus\u003c\/td\u003e\n\u003ctd colspan=\"5\"\u003eFirst \u003cstrong\u003e2 subjects\u003c\/strong\u003e: \u003cstrong\u003e3 to 5 times higher\u003c\/strong\u003e than \u003cstrong\u003e3\u003c\/strong\u003e comparable subjects on standard of care.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eFinancial and Trial Scale Data\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTrial extended to include a total of \u003cstrong\u003e12 subjects\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents and short-term investments as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e: \u003cstrong\u003e$93.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGross proceeds from underwritten public offering on \u003cstrong\u003eNovember 13, 2025\u003c\/strong\u003e: \u003cstrong\u003e$57.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAnticipated cash runway to the end of \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Net Loss: \u003cstrong\u003e$17.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 EPS: \u003cstrong\u003e-$0.21\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eShares Outstanding: \u003cstrong\u003e75.15 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMarket Cap: \u003cstrong\u003e$118.74 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEledon Pharmaceuticals, Inc. (ELDN) - VRIO Analysis: Recent Capital Raise and Financial Runway\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The $57.5 million gross proceeds from the November 2025 offering provides a strong buffer to fund operations into late 2026. This capital injection followed the reporting of Phase 2 BESTOW data showing an eGFR of approximately 69 mL\/min\/1.73m2 at 12 months in the treatment arm (n=51).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many clinical-stage biotechs raise capital, but securing this amount post-data release strengthens their negotiating position. The offering was priced at $1.65 per share.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; the specific timing and terms of the offering are unique to Eledon Pharmaceuticals. The offering included 15,152,485 shares of common stock and 15,151,515 pre-funded warrants.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Effective; management secured funding precisely when needed to plan for Phase 3, with net proceeds of approximately $53.6 million intended to support transplantation programs and advance the pipeline.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the runway is finite, but it buys time to hit the next value-creating milestone, such as anticipated FDA guidance and initiation of a Phase 3 kidney transplant trial in 2026.\u003c\/p\u003e\n\u003cp\u003eKey financial and offering details are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Proceeds\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$57.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNovember 2025 Offering\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Proceeds (Approximate)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$53.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNovember 2025 Offering\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Short-term Investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$93.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommon Stock Sold\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e15,152,485\u003c\/strong\u003e shares\u003c\/td\u003e\n\u003ctd\u003eNovember 2025 Offering\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-funded Warrants Sold (Aggregate)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15,151,515\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNovember 2025 Offering\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnderwriter Option (Maximum Additional Shares)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e4,545,600\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eNovember 2025 Offering\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAdditional relevant financial statistics from the period leading up to the capital raise include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet loss for the third quarter of 2025 was $17.5 million, or $0.21 per basic common share.\u003c\/li\u003e\n\u003cli\u003eResearch and development (R\u0026amp;D) expenses for the third quarter of 2025 were $15.0 million.\u003c\/li\u003e\n\u003cli\u003eThe Q3 2025 R\u0026amp;D expense included $1.1 million of non-cash stock-based compensation expense.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents and short-term investments decreased from $140.2 million as of December 31, 2024, to $93.4 million as of September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eThe comparable period in 2024 (Q3 2024) showed a net income of $77.0 million, which included a non-cash gain of $96.4 million related to changes in the fair value of warrant liabilities.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEledon Pharmaceuticals, Inc. (ELDN) - VRIO Analysis: Inclusion in Major Market Indexes\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Inclusion in the Russell 3000® and Russell 2000® Indexes in \u003cstrong\u003eJune 2025\u003c\/strong\u003e broadens investor visibility and potential institutional ownership. The Russell U.S. equity indices reconstitution, which included ELDN, is a significant market event given that approximately \u003cstrong\u003e$8.5 trillion\u003c\/strong\u003e is benchmarked to Russell indices, with roughly \u003cstrong\u003e$2 trillion\u003c\/strong\u003e tracking them passively.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; index inclusion is a milestone achieved by growing companies, but it signals a certain level of market acceptance.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; inclusion is based on objective market capitalization criteria.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Passive; this is a result of market performance, but the company is organized to capitalize on the increased visibility.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; index inclusion can be lost if market cap declines significantly.\u003c\/p\u003e\n\u003cp\u003eRecent market capitalization data for Eledon Pharmaceuticals, Inc. (ELDN) provides context for the index inclusion criteria:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization (Reported)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$111.13M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 2, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization (Reported)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$119.49 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 3, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization (Reported)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.12 Billion USD\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNovember 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization (1-Year Change)\u003c\/td\u003e\n\u003ctd\u003eDecreased by \u003cstrong\u003e-51.57%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of December 3, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFurther statistical context related to the index inclusion and market performance includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEledon Pharmaceuticals, Inc. was added to the \u003cstrong\u003eRussell 3000 Growth Index\u003c\/strong\u003e effective \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eEledon Pharmaceuticals, Inc. was added to the \u003cstrong\u003eRussell 2000 Index\u003c\/strong\u003e effective \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe annual rebalancing of Russell indices in June is often marked by heavy trading volume, with nearly \u003cstrong\u003e$220 billion\u003c\/strong\u003e worth of stocks traded at the market close during the 2024 reconstitution.\u003c\/li\u003e\n\u003cli\u003eThe company's market cap decreased by \u003cstrong\u003e-56%\u003c\/strong\u003e over the 30 days preceding December 2, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEledon Pharmaceuticals, Inc. (ELDN) - VRIO Analysis: Potential Next-Generation Standard of Care Positioning\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003ePotential Next-Generation Standard of Care Positioning\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ultimate goal - to replace existing, toxic cornerstone therapies - offers massive market potential if regulatory bodies agree with the Phase 2 data. Tegoprubart demonstrated a favorable safety and tolerability profile in the Phase 2 BESTOW trial, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with \u003cstrong\u003etacrolimus\u003c\/strong\u003e. Kidney function, as measured by estimated glomerular filtration rate (eGFR), was approximately \u003cstrong\u003e69 mL\/min\/1.732\u003c\/strong\u003e at 12-months for participants in the tegoprubart treatment arm (n=51). Updated data from the Phase 1b open-label trial demonstrated a mean 12-month eGFR of approximately \u003cstrong\u003e68 mL\/min\/1.73 m2\u003c\/strong\u003e post-transplant for patients on tegoprubart.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; few drugs successfully displace a deeply entrenched standard of care like \u003cstrong\u003etacrolimus\u003c\/strong\u003e. The data demonstrated potentially the first human cases of insulin independence achieved using an anti-CD40L monoclonal antibody immunosuppressive therapy without the use of \u003cstrong\u003etacrolimus\u003c\/strong\u003e in islet cell transplantation.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; requires overcoming regulatory hurdles and demonstrating clear superiority in a large Phase 3 trial. Eledon plans to advance tegoprubart into Phase 3 development following discussions with regulators on study design and data requirements.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Focused; the entire corporate narrative, from CEO statements to R\u0026amp;D spend, points to this singular goal. Research and development (R\u0026amp;D) expenses for the third quarter of 2025 were \u003cstrong\u003e$15.0 million\u003c\/strong\u003e. General and administrative expenses for the third quarter of 2025 were \u003cstrong\u003e$4.1 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, if achieved, as it creates a durable market position based on superior patient outcomes. The company expects current cash, cash equivalents and short-term investments to fund operations to the end of \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinance: Draft 13-Week Cash Flow Projection Incorporating Net Proceeds\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCash, cash equivalents and short-term investments totaled \u003cstrong\u003e$93.4 million\u003c\/strong\u003e as of September 30, 2025. On November 13, 2025, Eledon completed an underwritten public offering resulting in net proceeds of approximately \u003cstrong\u003e$53.6 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eWeek 1 (Inflow)\u003c\/td\u003e\n\u003ctd\u003eWeeks 2-13 (Outflow Estimate)\u003c\/td\u003e\n\u003ctd\u003eWeek 13 Ending Balance (Projected)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStarting Cash (As of 9\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$93.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancing Inflow (Net Proceeds)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$53.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Cash Available\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$147.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Weekly Operating Cash Burn (Based on Q3 2025 R\u0026amp;D\/G\u0026amp;A)\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.47 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Projected Cash Outflow (13 Weeks)\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$19.11 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Ending Cash Balance\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~$127.89 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516157026453,"sku":"eldn-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/eldn-vrio-analysis.png?v=1740169415","url":"https:\/\/dcf-model.com\/pt\/products\/eldn-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}